OBJECTIVE: To investigate the role of extracranial stereotactic body radiation therapy (SBRT) in the management of oligometastatic melanoma. METHODS: Patients affected by Stage IV melanoma, with less than three extracranial metastatic lesions, who received SBRT were included in this analysis. Acute and late toxicity, local control (LC), overall survival (OS) and progression-free survival (PFS) were analysed. RESULTS: 31 patients were included in the study. 16 patients (51.6%) were treated for lung meta-stases, 8 patients for liver metastases (25.8%) and 7 (22.6%) for nodal metastases. 38 lesions were irradiated. With a median follow-up time of 13 months, 11 patients (35.4%) were still alive, in four cases (12.9%) with no evidence of disease. Median OS was 10.6 months, and OS at 6, 12 and 24 months was 77, 41 and 21% respectively. LC at 12 and 24 months was 96.6 and 82.8%. 23 patients (74.2%) developed distant metastases. Median PFS was 5.8 months, and PFS at 6, 12 and 24 months was 48.2, 18.5 and 13.9% respectively. Number of irradiated lesions showed a statistically significant correlation only with LC (p = 0.03). Response of the irradiated lesion was related to OS (p = 0.019). Local response showed also a borderline correlation with PFS (p = 0.07). CONCLUSION: SBRT for extracranial metastases from melanoma is feasible and well tolerated. Response of the irradiated lesions is predictive of OS. Advances in knowledge: SBRT for melanoma extracranial metastases is feasible and the response of the irradiated lesions is predictive of OS.
OBJECTIVE: To investigate the role of extracranial stereotactic body radiation therapy (SBRT) in the management of oligometastatic melanoma. METHODS:Patients affected by Stage IV melanoma, with less than three extracranial metastatic lesions, who received SBRT were included in this analysis. Acute and late toxicity, local control (LC), overall survival (OS) and progression-free survival (PFS) were analysed. RESULTS: 31 patients were included in the study. 16 patients (51.6%) were treated for lung meta-stases, 8 patients for liver metastases (25.8%) and 7 (22.6%) for nodal metastases. 38 lesions were irradiated. With a median follow-up time of 13 months, 11 patients (35.4%) were still alive, in four cases (12.9%) with no evidence of disease. Median OS was 10.6 months, and OS at 6, 12 and 24 months was 77, 41 and 21% respectively. LC at 12 and 24 months was 96.6 and 82.8%. 23 patients (74.2%) developed distant metastases. Median PFS was 5.8 months, and PFS at 6, 12 and 24 months was 48.2, 18.5 and 13.9% respectively. Number of irradiated lesions showed a statistically significant correlation only with LC (p = 0.03). Response of the irradiated lesion was related to OS (p = 0.019). Local response showed also a borderline correlation with PFS (p = 0.07). CONCLUSION: SBRT for extracranial metastases from melanoma is feasible and well tolerated. Response of the irradiated lesions is predictive of OS. Advances in knowledge: SBRT for melanoma extracranial metastases is feasible and the response of the irradiated lesions is predictive of OS.
Authors: Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf Journal: N Engl J Med Date: 2012-06-04 Impact factor: 91.245
Authors: Ana P Kiess; Jedd D Wolchok; Christopher A Barker; Michael A Postow; Viviane Tabar; Jason T Huse; Timothy A Chan; Yoshiya Yamada; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-05 Impact factor: 7.038
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Joseph K Salama; Michael D Hasselle; Steven J Chmura; Renuka Malik; Neil Mehta; Kamil M Yenice; Victoria M Villaflor; Walter M Stadler; Philip C Hoffman; Ezra E W Cohen; Philip P Connell; Daniel J Haraf; Everett E Vokes; Samuel Hellman; Ralph R Weichselbaum Journal: Cancer Date: 2011-10-21 Impact factor: 6.860
Authors: Kirtesh R Patel; David H Lawson; Ragini R Kudchadkar; Bradley C Carthon; Daniel E Oliver; Derick Okwan-Duodu; Rafi Ahmed; Mohammad K Khan Journal: Neuro Oncol Date: 2015-05-25 Impact factor: 12.300
Authors: Matthias Guckenberger; Rainer J Klement; Michael Allgäuer; Nicolaus Andratschke; Oliver Blanck; Judit Boda-Heggemann; Karin Dieckmann; Marciana Duma; Iris Ernst; Ute Ganswindt; Peter Hass; Christoph Henkenberens; Richard Holy; Detlef Imhoff; Henning K Kahl; Robert Krempien; Fabian Lohaus; Ursula Nestle; Meinhard Nevinny-Stickel; Cordula Petersen; Sabine Semrau; Jan Streblow; Thomas G Wendt; Andrea Wittig; Michael Flentje; Florian Sterzing Journal: Radiother Oncol Date: 2015-09-15 Impact factor: 6.280
Authors: Robert D Timmerman; Costas S Bizekis; Harvey I Pass; Yuman Fong; Damian E Dupuy; Laura A Dawson; David Lu Journal: CA Cancer J Clin Date: 2009-04-10 Impact factor: 508.702
Authors: Kirtesh R Patel; Mudit Chowdhary; Jeffrey M Switchenko; Ragini Kudchadkar; David H Lawson; Richard J Cassidy; Roshan S Prabhu; Mohammad K Khan Journal: Melanoma Res Date: 2016-08 Impact factor: 3.599